Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic plc (NYSE:MDT) will participate in several virtual investor conferences in early June 2021. Key events include the Jefferies Virtual Healthcare Conference on June 2 at 1:30 pm EDT, featuring Sean Salmon. On June 3 at 3:30 pm EDT, Geoff Martha will present at the Bernstein 37th Annual Strategic Decisions Conference. Finally, on June 8 at 8:00 am EDT, he will speak at the Goldman Sachs 42nd Annual Health Care Conference. Live webcasts will be available, with replays accessible later on Medtronic's investor relations website.
On May 18, 2021, Medtronic (NYSE:MDT) presented two-year results from the Evolut Low Risk Trial at EuroPCR 2021, demonstrating that the Evolut TAVR system is non-inferior to open-heart surgery for low-risk patients with aortic stenosis. The study reported all-cause mortality or disabling stroke rates of 4.3% for TAVR versus 6.3% for surgery. Other positive outcomes included lower heart failure hospitalizations and valve thrombosis rates. With over 700 patients involved, these findings reinforce TAVR's effectiveness for low-risk patients, potentially impacting a market of 165,000 patients annually.
Medtronic plc (NYSE: MDT) has launched the GSR-DEFINE Study, expanding its real-world data collection to 5,000 patients with uncontrolled hypertension. The study builds on previous findings where the Symplicity Renal Denervation System demonstrated sustained blood pressure reductions over three years. Results from the latest research showed a mean decrease of 16.7 mmHg in office systolic blood pressure. Moreover, a new analysis indicated a 26% relative risk reduction in major cardiovascular events over three years, confirming the effectiveness of RDN for hypertensive patients.
Medtronic plc (NYSE:MDT) will report its financial results for Q4 and full fiscal year 2021 on May 27, 2021, with a news release at 5:45 a.m. CDT. The announcement will include key financial metrics for the period ending April 30, 2021. A video webcast will follow at 7:00 a.m. CDT to discuss these results, accessible via the investor relations page. Looking ahead, Medtronic has set dates for fiscal year 2022 Q1 through Q4 results reports between August 24, 2021 and May 26, 2022.
Medtronic plc (NYSE:MDT) announced a $3M contribution to COVID-19 relief, increasing its total support to $56M. The initiative focuses on underserved regions in India, Brazil, and the U.S., addressing medical supplies, treatment sites, and health worker training. Partnering with nonprofits, the Medtronic Foundation aims to improve healthcare equity and combat vaccine hesitancy. Additionally, it will match employee donations 2:1 to eligible nonprofits and engage employees in virtual volunteer efforts.
Medtronic plc (NYSE:MDT) announced the U.S. launch of the SonarMed™ airway monitoring system, the first device to utilize acoustic technology for real-time monitoring of endotracheal tube position and obstruction in neonates. Each year, 415,000 infants require mechanical ventilation, with 75,000 suffering unplanned extubations. The SonarMed system aims to reduce these events, improving patient outcomes and lowering healthcare costs. Clinicians report significant improvements in care efficiency and reduced need for x-rays. The system is FDA-cleared and comprised of a bedside monitor and a single-use sensor.
Medtronic has launched CareGuidePro, a mobile app and web portal designed to assist patients undergoing spinal cord stimulation therapy. This platform allows patients to log pain relief and provide feedback, which helps care teams manage treatments more effectively. The app includes features such as caregiver access, procedure-specific FAQs, and secure communication among care teams. A limited commercial release is underway, with a wider release expected later in summer 2021. Medtronic emphasizes that digital health solutions will enhance patient engagement and outcomes.
Medtronic (NYSE: MDT) has announced the CE Mark approval of the Evolut™ PRO+ TAVI System, expanding its TAVI platform for treating symptomatic severe aortic stenosis. The system offers four valve sizes and features an external tissue wrap for enhanced sealing. This new approval supports treatment for low-risk surgical patients and those with bicuspid aortic valves. The Evolut PRO+ aims to improve hemodynamic performance while minimizing vascular access challenges, ultimately broadening patient eligibility for transfemoral procedures.
Medtronic plc (NYSE:MDT) announced promising interim results from the OPTIMIZE PRO clinical study involving 171 patients treated with the Evolut™ PRO and PRO+ TAVR systems for severe aortic stenosis. Key findings revealed zero deaths or disabling strokes and a low pacemaker rate of 8.8% at 30 days. The study highlighted excellent hemodynamic performance, with most patients experiencing expedited discharges within a median of one day. Conducted at multiple sites in the U.S., Canada, and Europe, the study aims to refine TAVR care pathways to enhance patient outcomes.